210 related articles for article (PubMed ID: 37062035)
1. Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.
Weiss L; Heinrich K; Zhang D; Dorman K; Rühlmann K; Hasselmann K; Klauschen F; Kumbrink J; Jung A; Rudelius M; Mock A; Ormanns S; Kunz WG; Roessler D; Beyer G; Corradini S; Heinzerling L; Haas M; von Bergwelt-Baildon M; Boeck S; Heinemann V; Westphalen CB
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8225-8234. PubMed ID: 37062035
[TBL] [Abstract][Full Text] [Related]
2. Lessons learned: the first consecutive 1000 patients of the CCCMunich
Heinrich K; Miller-Phillips L; Ziemann F; Hasselmann K; Rühlmann K; Flach M; Biro D; von Bergwelt-Baildon M; Holch J; Herold T; von Baumgarten L; Greif PA; Jeremias I; Wuerstlein R; Casuscelli J; Spitzweg C; Seidensticker M; Renz B; Corradini S; Baumeister P; Goni E; Tufman A; Jung A; Kumbrink J; Kirchner T; Klauschen F; Metzeler KH; Heinemann V; Westphalen CB
J Cancer Res Clin Oncol; 2023 May; 149(5):1905-1915. PubMed ID: 35796778
[TBL] [Abstract][Full Text] [Related]
3. NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU.
Sultova E; Westphalen CB; Jung A; Kumbrink J; Kirchner T; Mayr D; Rudelius M; Ormanns S; Heinemann V; Metzeler KH; Greif PA; Burges A; Trillsch F; Mahner S; Harbeck N; Wuerstlein R
Arch Gynecol Obstet; 2021 May; 303(5):1331-1345. PubMed ID: 33277683
[TBL] [Abstract][Full Text] [Related]
4. A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich.
Zhang D; Dorman K; Heinrich K; Weiss L; Boukovala M; Haas M; Greif PA; Ziemann F; Beyer G; Roessler D; Goni E; Renz B; D'Haese JG; Kunz WG; Seidensticker M; Corradini S; Niyazi M; Ormanns S; Kumbrink J; Jung A; Mock A; Rudelius M; Klauschen F; Werner J; Mayerle J; von Bergwelt-Baildon M; Boeck S; Heinemann V; Westphalen CB
Target Oncol; 2023 Sep; 18(5):767-776. PubMed ID: 37594677
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
[TBL] [Abstract][Full Text] [Related]
6. The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review.
Lorkowski SW; Dermawan JK; Rubin BP
Virchows Arch; 2024 Feb; 484(2):369-375. PubMed ID: 37999736
[TBL] [Abstract][Full Text] [Related]
7. Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich
Dorman K; Zhang D; Heinrich K; Reeh L; Weiss L; Haas M; Beyer G; Rössler D; Goni E; Renz BW; D'Haese JG; Kunz WG; Seidensticker M; Corradini S; Niyazi M; Ormanns S; Kumbrink J; Jung A; Klauschen F; Werner J; Mayerle J; von Bergwelt-Baildon M; Boeck S; Heinemann V; Westphalen CB
Target Oncol; 2023 Mar; 18(2):257-267. PubMed ID: 36853374
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies.
Zaun G; Borchert S; Metzenmacher M; Lueong S; Wiesweg M; Zaun Y; Pogorzelski M; Behrens F; Schildhaus HU; Virchow I; Kasper S; Schuler M; Theurer S; Liffers S
Eur J Cancer; 2024 Mar; 200():113540. PubMed ID: 38316065
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
[TBL] [Abstract][Full Text] [Related]
10. Implementing precision oncology for sarcoma patients: the CCC
Berclaz LM; Burkhard-Meier A; Lange P; Di Gioia D; Schmidt M; Knösel T; Klauschen F; von Bergwelt-Baildon M; Heinemann V; Greif PA; Westphalen CB; Heinrich K; Lindner LH
J Cancer Res Clin Oncol; 2023 Nov; 149(15):13973-13983. PubMed ID: 37542550
[TBL] [Abstract][Full Text] [Related]
11. A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience.
Pauli C; Bochtler T; Mileshkin L; Baciarello G; Losa F; Ross JS; Pentheroudakis G; Zarkavelis G; Yalcin S; Özgüroğlu M; Beringer A; Scarato J; Mueller-Ohldach M; Thomas M; Moch H; Krämer A
Oncologist; 2021 May; 26(5):e769-e779. PubMed ID: 33687747
[TBL] [Abstract][Full Text] [Related]
12. [Cancer of unknown primary-The new ESMO guidelines].
Bochtler T; Pouyiourou M; Krämer A
Radiologie (Heidelb); 2023 May; 63(5):329-335. PubMed ID: 36930265
[TBL] [Abstract][Full Text] [Related]
13. Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary.
Moran S; Martinez-Cardús A; Boussios S; Esteller M
Nat Rev Clin Oncol; 2017 Nov; 14(11):682-694. PubMed ID: 28675165
[TBL] [Abstract][Full Text] [Related]
14. Six-year experience of Australia's first dedicated cancer of unknown primary clinic.
van Mourik A; Tonkin-Hill G; O'Farrell J; Waller S; Tan L; Tothill RW; Bowtell D; Fox S; Fellowes A; Fedele C; Schofield P; Sivakumaran T; Wong HL; Mileshkin L
Br J Cancer; 2023 Aug; 129(2):301-308. PubMed ID: 37225894
[TBL] [Abstract][Full Text] [Related]
15. Chronological improvement in precision oncology implementation in Japan.
Sunami K; Naito Y; Komine K; Amano T; Ennishi D; Imai M; Kage H; Kanai M; Kenmotsu H; Koyama T; Maeda T; Morita S; Sakai D; Kohsaka S; Tsuchihara K; Saigusa Y; Yoshino T
Cancer Sci; 2022 Nov; 113(11):3995-4000. PubMed ID: 35976133
[TBL] [Abstract][Full Text] [Related]
16. Genetics and beyond: Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center.
Kraus FBT; Sultova E; Heinrich K; Jung A; Westphalen CB; Tauber CV; Kumbrink J; Rudelius M; Klauschen F; Greif PA; König A; Chelariu-Raicu A; Czogalla B; Burges A; Mahner S; Wuerstlein R; Trillsch F
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397025
[TBL] [Abstract][Full Text] [Related]
17. Cancer of unknown primary-Epidemiological trends and relevance of comprehensive genomic profiling.
Binder C; Matthes KL; Korol D; Rohrmann S; Moch H
Cancer Med; 2018 Sep; 7(9):4814-4824. PubMed ID: 30019510
[TBL] [Abstract][Full Text] [Related]
18. Identification of barriers to implementation of precision oncology in patients with rare cancers.
Takamizawa S; Koyama T; Sunami K; Sudo K; Hirata M; Kubo T; Tao K; Cho H; Narita Y; Kato K; Yamazaki N; Ohe Y; Okusaka T; Matsui Y; Ogawa C; Yonemori K; Yamamoto N
Cancer Sci; 2024 Jun; 115(6):2023-2035. PubMed ID: 38538548
[TBL] [Abstract][Full Text] [Related]
19. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting.
VanderWalde A; Grothey A; Vaena D; Vidal G; ElNaggar A; Bufalino G; Schwartzberg L
J Pers Med; 2020 Nov; 10(4):. PubMed ID: 33260805
[TBL] [Abstract][Full Text] [Related]
20. Carcinomas of an unknown primary origin--diagnosis and treatment.
Massard C; Loriot Y; Fizazi K
Nat Rev Clin Oncol; 2011 Nov; 8(12):701-10. PubMed ID: 22048624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
